Moderna (MRNA) PT Raised to $52 at Chardan Capital After COVID-19 Vaccine Phase 2 IND Filed
Tweet Send to a Friend
Chardan Capital Markets analyst Geulah Livshits raised the price target on Moderna (NASDAQ: MRNA) to $52.00 (from $40.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
